Targeting metastatic colorectal cancer - Present and emerging treatment options

Pharmacogenomics and Personalized Medicine

Volumn 7, Issue 1, 2014, Pages 137-144

  Ciombor, Kristen K ^a   Berlin, Jordan ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Aflibercept; Bevacizumab; Biomarker; Cetuximab; Panitumumab; Regorafenib

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BIOLOGICAL PRODUCT; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PANITUMUMAB; PLACENTAL GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; REGORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

CANCER MORTALITY; CODON; COLORECTAL CANCER; DISEASE COURSE; EXON; GENE MUTATION; HUMAN; MAINTENANCE THERAPY; METASTASIS; MONOTHERAPY; ONCOGENE K RAS; PATIENT SELECTION; REVIEW; WILD TYPE;

EID: 84904167163     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S47582     Document Type: Review

References (46)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63(1): 11-30.
2. Lynch JP, Hoops TC. The genetic pathogenesis of colorectal cancer. Hematol Oncol Clin North Am. 2002; 16(4): 775-810.
3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990; 61(5): 759-767.
4. Weisenberger DJ, Siegmund KD, Campan M, etal. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006; 38(7): 787-793.
5. Noffsinger AE. Serrated polyps and colorectal cancer: new pathway to malignancy. Annu Rev Pathol. 2009; 4: 343-364.
6. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature. 2002; 418(6901): 934.
7. Domingo E, Niessen RC, Oliveira C, etal. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene. 2005; 24(24): 3995-3998.
8. Van Cutsem E, Köhne CH, Hitre E, etal. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14): 1408-1417.
9. Van Cutsem E, Köhne CH, Láng I, etal. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011; 29(15): 2011-2019.
10. Sobrero AF, Maurel J, Fehrenbacher L, etal. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(14): 2311-2319.
11. Bokemeyer C, Bondarenko I, Makhson A, etal. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2009; 27(5): 663-671.
12. Douillard JY, Siena S, Cassidy J, etal. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28(31): 4697-4705.
13. Douillard JY, Siena S, Tabernero J, etal. Overall survival analysis from PRIME: randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC). J Clin Oncol. 2013; 31 Suppl: abstr 3620.
14. Peeters M, Price TJ, Cervantes A, etal. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol. 2010; 28(31): 4706-4713.
15. Jonker DJ, O'Callaghan CJ, Karapetis CS, etal. Cetuximab for the treatment of colorectal cancer. N Engl J Med. 2007; 357(20): 2040-2048.
16. Van Cutsem E, Peeters M, Siena S, etal. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13): 1658-1664.
17. Price TJ, Peeters M, Kim TW, etal. ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Eur J Cancer. 2013; 49 Suppl 3: LBA 18.
18. Ye LC, Liu TS, Ren L, etal. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013; 31(16): 1931-1938.
19. Heinemann V, von Weikersthal LF, Decker T, etal. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). J Clin Oncol. 2013; 31 Suppl: abstr LBA3506.
20. Venook AP, Blanke CD, Niedzwiecki D, etal. Cancer and Leukemia Group B/Southwest Oncology Group Trial 80405: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer. 2005; 5(4): 292-294.
21. Venook AP, Blanke CD, Niedzwiecki D, etal. Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma. Clin Colorectal Cancer. 2007; 6(7): 536-538.
22. Douillard JY, Oliner KS, Siena S, etal. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11): 1023-1034.
23. Stintzing S, Jung A, Rossius L, etal. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: a randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. Eur J Cancer. 2013; 49 Suppl 3: LBA17.
24. Hurwitz H, Fehrenbacher L, Novotny W, etal. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350(23): 2335-2342.
25. Fuchs CS, Marshall J, Mitchell E, etal. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol. 2007; 25(30): 4779-4786.
26. Hochster HS, Hart LL, Ramanathan RK, etal. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008; 26(21): 3523-3529.
27. Saltz LB, Clarke S, Díaz-Rubio E, etal. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008; 26(12): 2013-2019.
28. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008; 26(4): 689-690.
29. Giantonio BJ, Catalano PJ, Meropol NJ, etal; Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007; 25(12): 1539-1544.
30. Grothey A, Sugrue MM, Purdie DM, etal. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008; 26(33): 5326-5334.
31. Cohn AL, Bekaii-Saab TS, Bendell JC, etal. Clinical outcomes in bevacizumab(BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRiTE data on BV beyond progression (BBP). J Clin Oncol. 2010; 28(Suppl 15): abstr 3596.
32. Bennouna J, Sastre J, Arnold D, etal; ML18147 Study Investigators. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1): 29-37.
33. Masi G, Vasile E, Loupakis F, etal. Randomized trial of two induction chemotherapy regimens in metastatic colorectal cancer: an updated analysis. J Natl Cancer Inst. 2011; 103(1): 21-30.
34. Falcone A, Ricci S, Brunetti I, etal; Gruppo Oncologico Nord Ovest. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007; 25(13): 1670-1676.
35. Souglakos J, Androulakis N, Syrigos K, etal. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer: a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006; 94(6): 798-805.
36. Falcone A, Cremolini C, Masi G, etal. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group. J Clin Oncol. 2013; 31 Suppl: abstr 3505.
37. Loupakis F, Cremolini C, Masi G, etal. FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (MCRC): Results of the phase III randomized TRIBE trial. J Clin Oncol. 2012; 31 Suppl 4: abstr 336.
38. Koopman M, Simkins LH, Tije AJ, etal. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group. J Clin Oncol. 2013; 31 Suppl: abst 3502.
39. Punt CJA, Simkens LHJ, May A, etal. Updated results including quality of life of the phase III CAIRO3 study of the Dutch Colorectal Cancer Group: maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer. Eur J Cancer. 2013; 49 Suppl 3: abstr 2166.
40. Johnsson A, Hagman H, Frödin JE, etal. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial. Ann Oncol. 2013; 24(9): 2335-2341.
41. Holash J, Davis S, Papadopoulos N, etal. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002; 99(17): 11393-11398.
42. Van Cutsem E, Tabernero J, Lakomy R, etal. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28): 3499-3506.
43. Tabernero J, Van Cutsem E, Lakomý R, etal. Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial. Eur J Cancer. 2014; 50(2): 320-331.
44. Wilhelm SM, Dumas J, Adnane L, etal. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011; 129(1): 245-255.
45. Grothey A, Van Cutsem E, Sobrero A, etal; CORRECT Study Group. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013; 381(9863): 303-312.
46. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487(7407): 330-337.